E-LIB Suche - Ergebnisse für: Homicsko, K.

1

B-cell infiltration is associated with survival outcomes fo..:

Gavrielatou, N. ; Fortis, E. ; Spathis, A....
Annals of Oncology. 35 (2024) 4 - p. 340-350 , 2024

2

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity res..:

Tichet, M ; Wullschleger, S ; Chryplewicz, A...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.immuni.2022.12.006. , 2023

Link: https://serval.unil.ch/n..

3

Response and Resistance to Trametinib in MAP2K1-Mutant Trip..:

Krebs, F.S ; Moura, B ; Missiaglia, E...
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms24054520. , 2023

Link: https://serval.unil.ch/n..

4

Deep and lasting response and acquired resistance to BRAFV6..:

Anchisi, S ; Wolfer, A ; Bisig, B...
info:eu-repo/semantics/altIdentifier/doi/10.1080/15384047.2023.2193116. , 2023

Link: https://serval.unil.ch/n..

5

11P Association of VISTA-expressing CD66b-positive neutroph..:

Homicsko, K. ; Zygoura, P. ; Tissot, S....
Immuno-Oncology and Technology. 16 (2022) - p. 100116 , 2022

Link: https://doi.org/10.1016/..

6

Safety and Efficacy of Ipilimumab plus Nivolumab and Sequen..:

Aedo-Lopez, V ; Gérard, C.L ; Boughdad, S...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers14051162. , 2022

Link: https://serval.unil.ch/n..

7

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipi..:

Homicsko, K ; Dummer, R ; Hoeller, C...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers14092300. , 2022

Link: https://serval.unil.ch/n..

8

Estimated Costs of the Ipilimumab-Nivolumab Therapy and Rel..:

Gautron Moura, B ; Gerard, C.L ; Testart, N...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers15010031. , 2022

Link: https://serval.unil.ch/n..

9

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipi..:

Homicsko, K ; Dummer, R ; Hoeller, C...
ARTN 2300. , 2022

Link: https://repository.icr.a..

10

First communication on the efficacy of combined 177Lutetium..:

Digklia, A ; Boughdad, S ; Homicsko, K...
info:eu-repo/semantics/altIdentifier/doi/10.1136/jitc-2022-005383. , 2022

Link: https://serval.unil.ch/n..

11

Late-onset and long-lasting immune-related adverse events f..:

Ghisoni, E. ; Wicky, A. ; Bouchaab, H....
European Journal of Cancer. 149 (2021) - p. 153-164 , 2021

Link: https://doi.org/10.1016/..

12

Turning tumors from cold to inflamed to improve immunothera..:

Gerard, C.L. ; Delyon, J. ; Wicky, A....
Cancer Treatment Reviews. 101 (2021) - p. 102227 , 2021

Link: https://doi.org/10.1016/..

13

Ovarian cancer with high-level focal ERBB2 amplification re..:

Thouvenin, L ; Charrier, M ; Clement, S...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.gore.2021.100787. , 2021

Link: https://serval.unil.ch/n..

14

Late-onset and long-lasting immune-related adverse events f..:

Ghisoni, E ; Wicky, A ; Bouchaab, H...
https://boris.unibe.ch/160865/. , 2021

Link: https://boris.unibe.ch/1..

15

Late-onset and long-lasting immune-related adverse events f..:

Ghisoni E ; Wicky A ; Bouchaab H...
info:eu-repo/semantics/altIdentifier/pmid/33865201. , 2021

Link: http://hdl.handle.net/11..